Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
CCR2 mediates hematopoietic stem and progenitor cell trafficking to sites of inflammation in mice
Yue Si, … , Kelsey Croft, Israel F. Charo
Yue Si, … , Kelsey Croft, Israel F. Charo
Published March 15, 2010
Citation Information: J Clin Invest. 2010;120(4):1192-1203. https://doi.org/10.1172/JCI40310.
View: Text | PDF
Research Article Inflammation

CCR2 mediates hematopoietic stem and progenitor cell trafficking to sites of inflammation in mice

  • Text
  • PDF
Abstract

HSCs are BM-derived, self-renewing multipotent cells that develop into circulating blood cells. They have been implicated in the repair of inflamed parenchymal tissue, but the signals that regulate their trafficking to sites of inflammation are unknown. As monocytes are recruited to sites of inflammation via chemoattractants that activate CCR2 on their surface, we investigated whether HSCs are also recruited to sites of inflammation through CCR2. Initial analysis indicated that in mice, CCR2 was expressed on subsets of HSCs and hematopoietic progenitor cells (HPCs) and that freshly isolated primitive hematopoietic cells (Lin–c-Kit+ cells) responded to CCR2 ligands in vitro. In vivo analysis indicated that after instillation of thioglycollate to cause aseptic inflammation and after administration of acetaminophen to induce liver damage, endogenous HSCs/HPCs were actively recruited to the peritoneum and liver, respectively, in WT but not Ccr2–/– mice. HSCs/HPCs recovered from the peritoneum successfully engrafted into the BM of irradiated primary and secondary recipients, confirming their self renewal and multipotency. Importantly, administration of exogenous WT, but not Ccr2–/–, HSCs/HPCs accelerated resolution of acetaminophen-induced liver damage and triggered the expression of genes characteristic of the macrophage M2 or repair phenotype. These findings reveal what we believe to be a novel role for CCR2 in the homing of HSCs/HPCs to sites of inflammation and suggest new functions for chemokines in promoting tissue repair and regeneration.

Authors

Yue Si, Chia-Lin Tsou, Kelsey Croft, Israel F. Charo

×

Figure 2

Chemotaxis of HSCs/HPCs to CCR2 ligands.

Options: View larger image (or click on image) Download as PowerPoint
Chemotaxis of HSCs/HPCs to CCR2 ligands.
c-Kit+Lin– BM cells were placed...
c-Kit+Lin– BM cells were placed into the upper chamber of a Boyden chemotaxis chamber. MCP-1 or MCP-3 was added at the indicated concentrations to the lower chambers, and cells that migrated into the lower chambers were quantified by FACS. (A) Phenotypic analysis of input c-Kit+Lin– cells for c-Kit, Sca-1, and CD34. (B) Analysis of cells that migrated to the lower chamber in response to JE (mMCP-1) or buffer control. (C) Quantification of primitive CD34–Sca1+c-Kit+Lin– (CD34 – SKL) cells that migrated to the lower well in response to the CCR2 ligands JE and MCP-3 or the CXCR4 ligand SDF-1. (D) Chemotaxis of CMPs and GMPs to JE, MCP-3, and SDF-1. (E) Quantification of clonogenic cells that underwent chemotaxis in response to JE, MCP-3, and SDF-1. Values are mean ± SD.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts